ARUP's Laboratory Test Directory

BCR-ABL1 Kinase Domain Mutation Analysis : 0040138
[ image for: Time Sensitive]
Time Sensitive
  


Mnemonic: BCRABL MUT

Methodology: Polymerase Chain Reaction/Sequencing
Performed: Varies
Reported: 10-12 days
Specimen Required: Collect: Lavender (EDTA) or bone marrow (EDTA).

Specimen Preparation: Transport 5 mL whole blood OR 3 mL bone marrow. (Min: 1 mL whole blood OR 1 mL bone marrow)

Storage/Transport Temperature: Refrigerated.

Unacceptable Conditions: Serum or plasma. Specimens collected in preservatives other than EDTA. Frozen specimens. Clotted or severely hemolyzed specimens.

Stability (collection to initiation of testing): Ambient: 1 hour; Refrigerated: 48 hours; Frozen: Unacceptable
Reference Interval:
By report
Interpretive Data: Refer to report

Refer to Statement B under Testing Information at http://www.aruplab.com.
Note: Assay detects more than 90 percent of the mutations that may lead to imatinib resistance.
CPT Code(s): 83891 Isolation; 83902 Reverse transcription; 83898 x4 Amplification; 83894 Gel detection; 83912 Interpretation and report. If sequencing is performed, add: 83892 Enzyme digestion; 83904 Sequencing and 83909 Capillary electrophoresis. Additional CPT code modifiers may be required for procedures performed to test for oncologic or inherited disorders.
Cross References: ABL Mutation (BCR-ABL1 Kinase Domain Mutation Analysis) , ABL1 Mutation Analysis for Imatinib (BCR-ABL1 Kinase Domain Mutation Analysis) , BCR-ABL1 Mutation (BCR-ABL1 Kinase Domain Mutation Analysis) , Gleevec Resistance Mutation Analysis (BCR-ABL1 Kinase Domain Mutation Analysis) , Imatinib Mesylate Resistance Analysis (BCR-ABL1 Kinase Domain Mutation Analysis) , Imatinib Resistance Analysis (BCR-ABL1 Kinase Domain Mutation Analysis)
 
 

 

 

 
All ARUP Sites:        www.aruplab.com     ·     www.arupconsult.com     ·     www.arup.utah.edu     ·     www.childx.org     ·     www.utahblood.org